BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36348503)

  • 21. The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.
    Jo S; Kim SO; Park KW; Lee SH; Hwang YS; Chung SJ
    Sci Rep; 2021 Apr; 11(1):7819. PubMed ID: 33837234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The genetic predictors of cognitive impairment in Parkinson's disease].
    Senkevich KA; Miliukhina IV; Pchelina SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8):109-117. PubMed ID: 30251988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
    Hoogland J; Boel JA; de Bie RMA; Schmand BA; Geskus RB; Dalrymple-Alford JC; Marras C; Adler CH; Weintraub D; Junque C; Pedersen KF; Mollenhauer B; Goldman JG; Tröster AI; Burn DJ; Litvan I; Geurtsen GJ;
    Mov Disord; 2019 Mar; 34(3):430-435. PubMed ID: 30653248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.
    Nombela C; Rowe JB; Winder-Rhodes SE; Hampshire A; Owen AM; Breen DP; Duncan GW; Khoo TK; Yarnall AJ; Firbank MJ; Chinnery PF; Robbins TW; O'Brien JT; Brooks DJ; Burn DJ; ; Barker RA
    Brain; 2014 Oct; 137(Pt 10):2743-58. PubMed ID: 25080285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic influences on cognitive decline in Parkinson's disease.
    Morley JF; Xie SX; Hurtig HI; Stern MB; Colcher A; Horn S; Dahodwala N; Duda JE; Weintraub D; Chen-Plotkin AS; Van Deerlin V; Falcone D; Siderowf A
    Mov Disord; 2012 Apr; 27(4):512-8. PubMed ID: 22344634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset.
    Parsian A; Racette B; Goldsmith LJ; Perlmutter JS
    Genomics; 2002 Mar; 79(3):458-61. PubMed ID: 11863377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.
    Fagan ES; Pihlstrøm L
    Eur J Neurol; 2017 Apr; 24(4):561-e20. PubMed ID: 28220571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
    Winder-Rhodes SE; Evans JR; Ban M; Mason SL; Williams-Gray CH; Foltynie T; Duran R; Mencacci NE; Sawcer SJ; Barker RA
    Brain; 2013 Feb; 136(Pt 2):392-9. PubMed ID: 23413260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson's Disease.
    Chuang YH; Lu AT; Paul KC; Folle AD; Bronstein JM; Bordelon Y; Horvath S; Ritz B
    J Parkinsons Dis; 2019; 9(2):389-400. PubMed ID: 30958317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations.
    Rudakou U; Yu E; Krohn L; Ruskey JA; Asayesh F; Dauvilliers Y; Spiegelman D; Greenbaum L; Fahn S; Waters CH; Dupré N; Rouleau GA; Hassin-Baer S; Fon EA; Alcalay RN; Gan-Or Z
    Brain; 2021 Mar; 144(2):462-472. PubMed ID: 33349842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease.
    Ezquerra M; Campdelacreu J; Gaig C; Compta Y; Muñoz E; Martí MJ; Valldeoriola F; Tolosa E
    Neurosci Lett; 2008 Dec; 448(1):20-3. PubMed ID: 18930114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease.
    Lunde KA; Chung J; Dalen I; Pedersen KF; Linder J; Domellöf ME; Elgh E; Macleod AD; Tzoulis C; Larsen JP; Tysnes OB; Forsgren L; Counsell CE; Alves G; Maple-Grødem J
    Alzheimers Dement; 2018 Oct; 14(10):1293-1301. PubMed ID: 29792872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognition in Parkinson's Disease.
    O'Callaghan C; Lewis SJG
    Int Rev Neurobiol; 2017; 133():557-583. PubMed ID: 28802933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.
    Paul KC; Rausch R; Creek MM; Sinsheimer JS; Bronstein JM; Bordelon Y; Ritz B
    J Parkinsons Dis; 2016 Apr; 6(2):349-59. PubMed ID: 27061069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder.
    Gan-Or Z; Montplaisir JY; Ross JP; Poirier J; Warby SC; Arnulf I; Strong S; Dauvilliers Y; Leblond CS; Hu MTM; Högl B; Stefani A; Monaca CC; De Cock VC; Boivin M; Ferini-Strambi L; Plazzi G; Antelmi E; Young P; Heidbreder A; Barber TR; Evetts SG; Rolinski M; Dion PA; Desautels A; Gagnon JF; Dupré N; Postuma RB; Rouleau GA
    Neurobiol Aging; 2017 Jan; 49():218.e13-218.e15. PubMed ID: 27814994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.